NAFTA | USMCA


We can't afford to let the new NAFTA drive up drug prices
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
The IP implications of the USMCA: Who needs to do what
The USMCA most closely reflects US IP laws, subjecting the US to almost no revisions of its current domestic intellectual property laws.
An historic opportunity to transform trade when we stop NAFTA II
We can stop NAFTA II and replace corporate trade with a new model that raises working conditions and protects the environment.
A no-go for the US: What is the Trans-Pacific Partnership and why did it fail?
With the US as the centerpiece, the TPP would have given the country a more significant stake in Asia and the Pacific in much the same way as NAFTA did in America.
NAFTA renewed. Now what?
The outcome of the “Trump moment” is likely, for all its protectionist rhetoric, to end up further legitimating free trade.
There’s a hidden cost in Trump’s new trade agreement with Canada and Mexico
Investment treaties with ISDS provisions make it hard to tax foreign firms and worsen human rights and labor practices.
The fossil fuel era is coming to an end, but the lawsuits are just beginning
Westmoreland Coal is suing Canada because it did not receive a transition payment following Alberta's coal phaseout plan. For the province, coal mining companies have no role to play in the energy transition.
The new NAFTA: A license to discriminate on the basis of sex
Final text weakens and nullifies protections against work discrimination.
Canada looks to sidestep USMCA tripwire in trade talks with China
Sector agreements signed between China and Canada could be rolled into a broader free trade agreement down the road — meaning that sectoral negotiations could lay the groundwork for comprehensive talks.
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts to­wards affordable health care and medicine.